Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human GSK3745417 monotherapy dose-escalation in advanced solid tumors
NL-OMON56334Phase 1Recruiting
- Sponsor
- GSK
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GSK3745417 in Nonhematologic neoplasms, sponsored by GSK. Primary endpoints: Dose-limiting toxicities, Adverse events and 1 more. Started Sep 2020; status: recruiting.
02
Drugs
GSK3745417
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON56334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56334.